Filing Analysis
Milestone Scientific Inc. dismissed its independent auditor, CBIZ CPAs P.C., and appointed Grassi & Co., CPAs, P.C. for the 2026 fiscal year. Notably, the outgoing auditor's report for the 2025 fiscal year included a 'going concern' qualification.
Red Flags
- Going concern qualification in the most recent (2025) audit report.
- Auditor change occurring while the company is under a going concern warning.
- The company is a micro-cap entity (MLSS) which increases the risk associated with financial instability.
Key Facts
- Dismissed CBIZ CPAs P.C. effective May 15, 2026.
- Engaged Grassi & Co., CPAs, P.C. for the fiscal year ending December 31, 2026.
- The 2025 audit report contained an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.
- The company stated there were no disagreements with CBIZ CPAs on accounting principles or practices during the 2025 fiscal year or subsequent interim period.
- CBIZ CPAs had originally become the auditor in April 2025 following its acquisition of Marcum LLP's attest business.
Milestone Scientific Inc. implemented a stock option repricing program for its CEO and SVP, lowering exercise prices to $0.31 and accelerating vesting. The company also established a new performance-based incentive plan with a pool of over 17.2 million shares, representing significant potential dilution for shareholders.
Red Flags
- Option repricing occurred less than one year after the original grants (August 2025 to April 2026).
- Significant potential dilution from the 17.2M share PRSU pool.
- Acceleration of vesting schedules for top executives concurrent with the price reduction.
- The repricing effectively removes the 'at-risk' nature of the original equity incentives following a decline in stock price.
Key Facts
- CEO Eric Hines and SVP Jason Papes had 4.0 million total options repriced from $0.46-$0.50 down to $0.31 per share.
- Vesting for the repriced options was accelerated from a 3-year schedule to a 2-year schedule, with immediate vesting increased from 200,000 to 500,000 shares per executive.
- A new 2026 Performance Incentive Sub-Plan was created with an aggregate pool of 17,234,635 shares, subject to stockholder approval.
- CEO Eric Hines was granted 5,170,391 PRSUs, while VP Finance Keisha Harcum and SVP Jason Papes each received 3,016,061 PRSUs.
- Performance milestones for the PRSUs include achieving net sales of $11M, $13M, and $15M, reaching a $50M market capitalization, and completing a 'Qualified Acquisition' with >$10M in revenue.
Milestone Scientific Inc. closed a $2.15 million private placement of units at $0.27 per unit, involving significant insider participation and debt conversion. The company amended existing insider bridge notes to lower the conversion floor from $0.50 to $0.27 to facilitate the transaction.
Red Flags
- Use of proceeds for 'past due accounts payable' indicates immediate liquidity distress.
- Related-party transaction involving directors Neal Goldman, Benedetta Casamento, and Dr. Didier Demesmin.
- Favorable amendment of debt terms for insiders, lowering the conversion price by 46% ($0.50 to $0.27).
- The offering was conducted without a placement agent, suggesting limited institutional interest.
Key Facts
- The company issued 7,962,963 units at $0.27 per unit, each consisting of one share and one warrant.
- Total gross proceeds were $2,150,000, consisting of $1,799,000 in cash and $351,000 in debt conversion.
- Warrants are exercisable at $0.3375 per share for a period of three years.
- Directors and officers purchased $150,000 in units for cash and converted $351,000 of 2025 Convertible Bridge Notes.
- The conversion floor for the insider bridge notes was specifically amended from $0.50 to $0.27 for this placement.
- Proceeds are earmarked for general working capital and the payment of 'past due accounts payable'.
Milestone Scientific Inc. entered into an amendment to its Memorandum of Understanding with Innovest S.p.A. to facilitate a future securities offering. The amendment modifies lock-up provisions and offering definitions related to a significant 11.31% shareholder block.
Red Flags
- The amendment is a precursor to a likely dilutive securities offering.
- Complex governance structure where a third party (Innovest) holds blockage rights over a major shareholder (BP4 S.r.l.) currently in liquidation.
Key Facts
- On March 31, 2026, the Company amended its MOU with Innovest S.p.A.
- Innovest S.p.A. holds consent/blockage rights over BP4 S.r.l., which owns 11.31% of the Company's common stock.
- The amendment revises the definitions of 'Qualified Offering' and 'Other Locked-Up Parties'.
- The stated purpose of the amendment is to facilitate an upcoming offering by the Company.
Milestone Scientific Inc. has officially increased its authorized common stock from 100,000,000 to 125,000,000 shares following a Certificate of Amendment filed in Delaware. This action follows stockholder approval previously obtained at the company's annual meeting on December 18, 2025.
Red Flags
- Potential for significant future dilution as the company now has the capacity to issue 25 million additional shares.
Key Facts
- Authorized common stock increased by 25,000,000 shares (a 25% increase in total authorized capacity).
- The Certificate of Amendment was filed and became effective on March 10, 2026.
- The amendment was previously approved by stockholders during the December 18, 2025, annual meeting.
- The filing was made under Item 5.03 (Amendments to Articles of Incorporation).